 |
 |
 |
 |
 |
 |
||
 |
 |
 |
 |
 |
| 5 | 1/1 | 返回列表 |
| 查看: 755 | 回復(fù): 2 | |||
| 本帖產(chǎn)生 1 個 翻譯EPI ，點擊這里進(jìn)行查看 | |||
| 當(dāng)前只顯示滿足指定條件的回帖，點擊這里查看本話題的所有回帖 | |||
snicl銀蟲 (小有名氣)
|
[求助]
急求漢譯英 ，500漢字
|
||
| 探討血清DPPIV濃度與慢性阻塞性肺疾病（COPD）不同疾病狀態(tài)下的相關(guān)性，分析其對COPD病情的判斷能力和診斷準(zhǔn)確度，為COPD篩選血清標(biāo)志物。方法 收集包頭市中心醫(yī)院呼吸科2013年1月至2013年12月門診和住院的病例，診斷為COPD的急性加重期患者42例為AECOPD組，經(jīng)相應(yīng)治療,臨床癥狀緩解后，全部歸為COPD治療緩解組。已超過3個月無急性加重的穩(wěn)定期COPD隨訪患者32例為COPD穩(wěn)定組。包頭市中心醫(yī)院體檢中心隨機選取中老年健康者29例為健康對照組。采用酶聯(lián)免疫吸附實驗法測定DPPIV濃度。比較健康組、COPD穩(wěn)定組、AECOPD組血清DPPIV濃度差異。比較AECOPD組治療前、后血清DPPIV濃度差異。觀察DPPIV濃度與年齡的相關(guān)性。采用ROC曲線分析法評價DPPIV濃度對COPD的診斷價值。結(jié)果 COPD穩(wěn)定組、AECOPD組、COPD治療緩解組血清DPPIV濃度較健康對照組明顯降低（P<0.001）。AECOPD治療后DPPIV濃度較治療前升高（P<0.001）。DPPIV濃度與年齡、性別以及吸煙史無相關(guān)性（P>0.05）。 AECOPD和COPD穩(wěn)定期，基于DPPIV濃度的ROC曲線下面積均超過0.9，特異度高達(dá)0.931，靈敏度達(dá)0.75以上。結(jié)論 COPD患者血清DPPIV濃度明顯降低。血清DPPIV濃度與性別、年齡無關(guān)，對COPD有很高的診斷價值，為COPD疾病的一種很好的血清學(xué)標(biāo)志物。血清DPPIV為COPD的保護性因素。 |
回復(fù)此樓» 猜你喜歡
材料調(diào)劑
已經(jīng)有5人回復(fù)
-
081700 調(diào)劑 267分
已經(jīng)有8人回復(fù)
-
請教下大家 2026年國家基金申請是雙盲審嗎？
已經(jīng)有5人回復(fù)
-
276求調(diào)劑。有半年電池和半年高分子實習(xí)經(jīng)歷
已經(jīng)有10人回復(fù)
-
一志愿南航材料專317分求調(diào)劑
已經(jīng)有4人回復(fù)
-
求調(diào)劑
已經(jīng)有4人回復(fù)
-
生物學(xué)學(xué)碩求調(diào)劑
已經(jīng)有5人回復(fù)
-
284求調(diào)劑
已經(jīng)有10人回復(fù)
-
一志愿山東大學(xué)藥學(xué)學(xué)碩求調(diào)劑
已經(jīng)有4人回復(fù)
-
07化學(xué)280分求調(diào)劑
已經(jīng)有4人回復(fù)
ssssllllnnnn 
至尊木蟲 (知名作家)
Translator and Proofreader
- 翻譯EPI: 1690
- 應(yīng)助: 452 (碩士)
- 金幣: 31580.9
- 紅花: 100
- 帖子: 7681
- 在線: 19966.6小時
- 蟲號: 3328089
- 注冊: 2014-07-17
- 專業(yè): 腫瘤發(fā)生
【答案】應(yīng)助回帖
★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★
真強必勝: 金幣+5, 謝謝 2014-09-23 12:48:32
snicl: 金幣+40, ★★★很有幫助 2014-09-23 15:31:18
真強必勝: 金幣+5, 謝謝 2014-09-23 12:48:32
snicl: 金幣+40, ★★★很有幫助 2014-09-23 15:31:18
| 【Objective】The purpose of the present study was to explore the correlation between serum DPPIV and chronic obstructive pulmonary disease (COPD) at its various disease states, analyze its applications in the prediction and diagnosis of COPD disease, and test the possibility of DPPIV as the serological marker for COPD by screening. 【Methods】 Samples from outpatients and inpatients were collected from Pulmonary Department, Baotou Central Hospital, from January 2013 to December 2013. 42 cases were initially diagnosed with acute exacerbation of COPD, thereafter were called AECOPD group in this study. After appropriate treatment, clinical remission occurred in all patients and therefore were classified as COPD remission group. Those 32 patients who have been followed up and been stable for more than three months without acute exacerbation were COPD stable group. 29 mid and elderly healthy subjects randomly selected from Physical Examination Center, Baotou Central Hospital were used as healthy control group. DPPIV concentration was measured by enzyme-linked immunosorbent assay (ELISA) and the difference in serum concentration of DPPIV was compared among healthy group, COPD stable group, and AECOPD group. The difference in serum DPPIV concentration of AECOPD group before and after treatment was also compared. The correlation between DPPIV concentration and age was analyzed. The diagnostic value of DPPIV concentration of COPD was evaluated by ROC curve analysis. 【Results】 Serum DPPIV concentration was significantly lower in stable COPD group, AECOPD group and COPD remission group as compared with that in healthy control group (P<0.001). Serum DPPIV concentration in AECOPD group was increased after treatment as compared with before treatment (P<0.001). There was no significant correlation between DPPIV concentration and age, gender, or smoking history (P> 0.05). For both AECOPD and stable COPD, the under curve area in ROC, which is based on DPPIV concentration, was more than 0.9, with a specificity of up to 0.931 and sensitivity of greater than 0.75. 【Conclusions】 Serum DPPIVP concentration in patients with COPD is decreased significantly and there is no correlation between serum DPPIV concentration and sex or age. Serum DPPIV is not only a protective factor, but also is of high value as a good serological marker for the diagnosis of COPD. |
3樓2014-09-22 12:57:05
wanfuping
木蟲 (小有名氣)
- 翻譯EPI: 35
- 應(yīng)助: 0 (幼兒園)
- 金幣: 2378.1
- 紅花: 3
- 帖子: 243
- 在線: 329.2小時
- 蟲號: 2050897
- 注冊: 2012-10-09
- 性別: GG
- 專業(yè): 人工智能與知識工程
【答案】應(yīng)助回帖
★ ★ ★ ★ ★ ★ ★ ★ ★ ★
snicl: 金幣+10, 翻譯EPI+1, ★有幫助 2014-09-23 15:30:30
snicl: 金幣+10, 翻譯EPI+1, ★有幫助 2014-09-23 15:30:30
| After having discussed the correlation between the concentration of DPPIV in the serum and different morbid states of COPD, the concentration’s ability of providing evidences for diagnosing the disease and its accuracy are analyzed in this paper so as to select serum marker for COPD. Based on collected case data of both outpatients and hospitalized patients from pneumology department of central hospital in Baotou City from January to December, 2013, 42 cases diagnosed with acute exacerbation patients of COPD are marked as AECOPD group, and after having received corresponding treatment and clinical symptoms eased up, the same 42 patients are marketed as treated group of COPD, and 32 visiting patients who haven’t caught acute exacerbation symptom for over 3 months are marked as stable group of COPD, and finally, 29 middle-aged and elderly and healthy persons randomly selected from Physical Examination Center (PEC) of the hospital are marked as healthy control group. Then, measure the concentration of DPPIV with the enzyme-linked immunosorbent assay (ELISA) method, compare the concentration difference among persons from healthy control group, stable group, AECOPD group, and the concentration difference before and after the corresponding treatment as well. Observe the correlation between the concentration of DPPIV and the age, and evaluate the concentration’s ability of providing evidences for diagnosing the disease-COPD with ROC curve analytical approach. The results show that, compared with people from healthy control group, concentrations of DPPIV of patients from stable group, AECOPD group, treated group are much lower ( P<0.001), and after having received treatment, the concentration of the patients from AECOPD group have increased (P<0.001), and the concentration is unrelated to age, gender and smoking history (P>0.05). In addition, the area under the concentration-based ROC curve has reached 0.9 and the degree of specificity 0.931and the degree of sensitivity above 0.75. In a word, concentration of DPPIV of COPD patient is lower than healthy person, unrelated to age and gender, and thus can serve as a good serum marker matter and can provide rich evidence for diagnosing COPD. DPPIV in the serum serves as a protective matter for COPD. |
2樓2014-09-22 09:28:57
| 最具人氣熱帖推薦 [查看全部] | 作者 | 回/看 | 最后發(fā)表 | |
|---|---|---|---|---|
|
[考研] 材料292調(diào)劑 +4 | 橘頌思美人 2026-03-23 | 4/200 |
|
|---|---|---|---|---|
|
|
[考研] 0703化學(xué)求調(diào)劑 +4 | 奶油草莓. 2026-03-22 | 5/250 |
|
|
|
[考研] 一志愿中國石油大學(xué)（華東） 本科齊魯工業(yè)大學(xué) +4 | 石能偉 2026-03-17 | 4/200 |
|
|
[考研] 306求調(diào)劑 +9 | chuanzhu川燭 2026-03-18 | 9/450 |
|
|
|
[考研] 求調(diào)劑 +5 | Zhangbod 2026-03-21 | 7/350 |
|
|
|
[考研] 求調(diào)劑 +4 | 要好好無聊 2026-03-21 | 4/200 |
|
|
|
[考研] 一志愿華中科技大學(xué)，080502，354分求調(diào)劑 +5 | 守候夕陽CF 2026-03-18 | 5/250 |
|
|
|
[考研] 一志愿華南師大 070300（化學(xué)）304分求調(diào)劑 +3 | 0703武芊慧雪304 2026-03-18 | 3/150 |
|
|
|
[考研] 一志愿重慶大學(xué)085700資源與環(huán)境專碩，總分308求調(diào)劑 +3 | 墨墨漠 2026-03-18 | 3/150 |
|
|
|
[考研] 304求調(diào)劑 +6 | 曼殊2266 2026-03-18 | 6/300 |
|
|
|
[考研] 330求調(diào)劑 +4 | 小材化本科 2026-03-18 | 4/200 |
|
|
|
[考研] 304求調(diào)劑 +7 | 司空. 2026-03-18 | 7/350 |
|
|
|
[考研] 求調(diào)劑一志愿南京航空航天大學(xué)289分 +3 | @taotao 2026-03-19 | 3/150 |
|
|
|
[考研] 一志愿西南交通 專碩 材料355 本科雙非 求調(diào)劑 +5 | 西南交通專材355 2026-03-19 | 5/250 |
|
|
|
[考研] 295材料求調(diào)劑，一志愿武漢理工085601專碩 +5 | Charlieyq 2026-03-19 | 5/250 |
|
|
|
[考研] 353求調(diào)劑 +3 | 拉鉤不許變 2026-03-20 | 3/150 |
|
|
|
[考研] 一志愿吉林大學(xué)材料學(xué)碩321求調(diào)劑 +11 | Ymlll 2026-03-18 | 15/750 |
|
|
|
[考研] 0856調(diào)劑，是學(xué)校就去 +8 | sllhht 2026-03-19 | 9/450 |
|
|
|
[考研] 生物學(xué)調(diào)劑招人！�。� +3 | 山海天嵐 2026-03-17 | 4/200 |
|
|
|
[考研] 288求調(diào)劑，一志愿華南理工大學(xué)071005 +5 | ioodiiij 2026-03-17 | 5/250 |
|